2 news items
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
TPST
20 Jun 24
remain in survival follow-up in the amezalpat arm, compared to 9/30 patients in the control arm.
0.65 hazard ratio for OS, revealing
Tempest Therapeutics Announces Data From Phase 1b/2 Study Of Amezalpat (TPST-1120); Shows Six-Month Improvement In Median Overall Survival When Combined With Atezolizumab And Bevacizumab In First-Line Treatment Of Unresectable Or Metastatic Hepatocellular Carcinoma
TPST
20 Jun 24
0.65 hazard ratio, maintained since 0.59 observed in primary analysis 10 months earlierEarly and persistent separation
- Prev
- 1
- Next